

Julia C Gage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/124304/publications.pdf>

Version: 2024-02-01

119
papers

5,317
citations

66343

42
h-index

95266

68
g-index

122
all docs

122
docs citations

122
times ranked

4341
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Papillomavirus Testing in the Prevention of Cervical Cancer. Journal of the National Cancer Institute, 2011, 103, 368-383.	6.3	583
2	Number of Cervical Biopsies and Sensitivity of Colposcopy. Obstetrics and Gynecology, 2006, 108, 264-272.	2.4	289
3	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. Journal of the National Cancer Institute, 2019, 111, 923-932.	6.3	249
4	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. Journal of the National Cancer Institute, 2014, 106, dju153-dju153.	6.3	200
5	Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines. Journal of Lower Genital Tract Disease, 2013, 17, S28-S35.	1.9	167
6	World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. International Journal of Gynecology and Obstetrics, 2016, 132, 252-258.	2.3	134
7	The Accuracy of Colposcopic Grading for Detection of High-Grade Cervical Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease, 2009, 13, 137-144.	1.9	119
8	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Journal of the National Cancer Institute, 2018, 110, 501-508.	6.3	116
9	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 132-143.	1.9	116
10	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine, 2020, 22, 100293.	7.1	109
11	A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infectious Diseases, 2012, 12, 33.	2.9	96
12	A Study of Genotyping for Management of Human Papillomavirus-Positive, Cytology-Negative Cervical Screening Results. Journal of Clinical Microbiology, 2015, 53, 52-59.	3.9	89
13	Clinical Human Papillomavirus Detection Forecasts Cervical Cancer Risk in Women Over 18 Years of Follow-Up. Journal of Clinical Oncology, 2012, 30, 3044-3050.	1.6	87
14	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S36-S42.	1.9	85
15	Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS. Journal of Lower Genital Tract Disease, 2013, 17, S78-S84.	1.9	75
16	Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detection and Prevention, 2003, 27, 466-471.	2.1	73
17	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women Who Test Pap-Negative But Are HPV-Positive. Journal of Lower Genital Tract Disease, 2013, 17, S56-S63.	1.9	73
18	Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States. Journal of Lower Genital Tract Disease, 2017, 21, 216-222.	1.9	71

#	ARTICLE	IF	CITATIONS
19	Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. <i>Aids</i> , 2012, 26, 2185-2192.	2.2	70
20	A cohort study of cervical screening using partial HPV typing and cytology triage. <i>International Journal of Cancer</i> , 2016, 139, 2606-2615.	5.1	68
21	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1184-1191.	1.6	65
22	Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. <i>International Journal of Cancer</i> , 2017, 141, 701-710.	5.1	62
23	Follow-up Testing After Colposcopy. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S69-S77.	1.9	59
24	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S50-S55.	1.9	59
25	Detection of Precancerous Cervical Lesions Is Differential by Human Papillomavirus Type. <i>Cancer Research</i> , 2009, 69, 3262-3266.	0.9	56
26	Human Papillomavirus Genotype Attribution and Estimation of Preventable Fraction of Anal Intraepithelial Neoplasia Cases Among HIV-Infected Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2013, 207, 392-401.	4.0	56
27	ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 230-234.	1.9	56
28	Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions. <i>Annals of Internal Medicine</i> , 2017, 166, 118.	3.9	53
29	Risk Factors for Anal HPV Infection and Anal Precancer in HIV-Infected Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2013, 208, 1768-1775.	4.0	52
30	Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 126, 156-160.	2.3	52
31	Assuring Adequate Health Insurance: Results of the National Survey of Children With Special Health Care Needs. <i>Pediatrics</i> , 2005, 115, 1233-1239.	2.1	51
32	Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. <i>International Journal of Cancer</i> , 2012, 131, 2903-2909.	5.1	51
33	The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen-and-treat strategies. <i>International Journal of Cancer</i> , 2012, 130, 2111-2117.	5.1	50
34	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. <i>Annals of Internal Medicine</i> , 2018, 168, 20.	3.9	50
35	Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S43-S49.	1.9	49
36	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. <i>Gynecologic Oncology</i> , 2015, 138, 573-578.	1.4	49

#	ARTICLE	IF	CITATIONS
37	Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 481.e1-481.e9.	1.3	48
38	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 144-147.	1.9	48
39	Comparison of the cobas Human Papillomavirus (HPV) Test with the Hybrid Capture 2 and Linear Array HPV DNA Tests. <i>Journal of Clinical Microbiology</i> , 2012, 50, 61-65.	3.9	47
40	A Population-Based Study of Visual Inspection With Acetic Acid (VIA) for Cervical Screening in Rural Nigeria. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 507-512.	2.5	47
41	Why does cervical cancer occur in a state-of-the-art screening program?. <i>Gynecologic Oncology</i> , 2017, 146, 546-553.	1.4	47
42	Interrater agreement of anal cytology. <i>Cancer Cytopathology</i> , 2013, 121, 72-78.	2.4	46
43	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1304-1310.	2.5	44
44	Association of <scp>HPV35</scp> with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention. <i>International Journal of Cancer</i> , 2020, 147, 2677-2686.	5.1	44
45	World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 118, 97-102.	2.3	42
46	Peer activity in the evenings and participation in aggressive and problem behaviors. <i>Journal of Adolescent Health</i> , 2005, 37, 517.e7-517.e14.	2.5	40
47	Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected <scp>HPV</scp> infection. <i>International Journal of Cancer</i> , 2015, 136, 1665-1671.	5.1	39
48	The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. <i>International Journal of Cancer</i> , 2015, 137, 893-902.	5.1	38
49	The Clinical Meaning of a Cervical Intraepithelial Neoplasia Grade 1 Biopsy. <i>Obstetrics and Gynecology</i> , 2011, 118, 1222-1229.	2.4	35
50	Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology. <i>Obstetrics and Gynecology</i> , 2017, 130, 1218-1225.	2.4	35
51	Analytic and Clinical Performance of cobas HPV Testing in Anal Specimens from HIV-Positive Men Who Have Sex with Men. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2892-2897.	3.9	29
52	5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 69, 631-638.	5.8	29
53	The development of "automated visual evaluation" for cervical cancer screening: The promise and challenges in adapting deep-learning for clinical testing. <i>International Journal of Cancer</i> , 2022, 150, 741-752.	5.1	29
54	Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S64-S68.	1.9	28

#	ARTICLE	IF	CITATIONS
55	Cervical Histopathology Variability Among Laboratories: A Population-Based Statewide Investigation. <i>American Journal of Clinical Pathology</i> , 2013, 139, 330-335.	0.7	28
56	Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. <i>Preventive Medicine</i> , 2018, 114, 149-155.	3.4	28
57	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. <i>Infectious Agents and Cancer</i> , 2020, 15, 60.	2.6	27
58	Comparative Performance of Human Papillomavirus DNA Testing Using Novel Sample Collection Methods. <i>Journal of Clinical Microbiology</i> , 2011, 49, 4185-4189.	3.9	26
59	Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years. <i>Cancer Prevention Research</i> , 2018, 11, 165-170.	1.5	26
60	The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. <i>Cancer Cytopathology</i> , 2014, 122, 842-850.	2.4	25
61	Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the <U><K><C>linical <P>ractice <R>esearch <D>atalink. <i>International Journal of Cancer</i> , 2018, 142, 1174-1181.	5.1	25
62	Risk of Cervical Intraepithelial Neoplasia 2 or Worse by Cytology, Human Papillomavirus 16/18, and Colposcopy Impression. <i>Obstetrics and Gynecology</i> , 2018, 132, 725-735.	2.4	25
63	A Comparison of Dacron versus Flocked Nylon Swabs for Anal Cytology Specimen Collection. <i>Acta Cytologica</i> , 2011, 55, 364-367.	1.3	24
64	Risk of Precancer Determined by HPV Genotype Combinations in Women with Minor Cytologic Abnormalities. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1095-1101.	2.5	24
65	Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 26-32.	1.9	24
66	A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria. <i>Infectious Agents and Cancer</i> , 2011, 6, 12.	2.6	23
67	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 42-49.	2.5	23
68	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations. <i>Obstetrics and Gynecology</i> , 2016, 128, 1248-1257.	2.4	22
69	Comparison of Measurements of Human Papillomavirus Persistence for Postcolposcopic Surveillance for Cervical Precancerous Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1668-1674.	2.5	20
70	Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 154-161.	1.9	20
71	The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 40-46.	2.3	20
72	Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results. <i>Journal of the National Cancer Institute</i> , 2019, 111, 820-827.	6.3	20

#	ARTICLE	IF	CITATIONS
73	A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. <i>Preventive Medicine</i> , 2021, 144, 106438.	3.4	20
74	A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry. <i>Human Pathology</i> , 2013, 44, 2542-2548.	2.0	19
75	The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 282-287.	1.9	19
76	Preventing Cervical Cancer Globally by Acting Locally: If Not Now, When?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1524-1527.	6.3	18
77	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	18
78	Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador: a nested study within the CAPE HPV screening program. <i>BMC Public Health</i> , 2015, 15, 1058.	2.9	17
79	Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 145-150.	1.9	17
80	Cervical cancer prevention in El Salvador (CAPE)â€”An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country. <i>Gynecologic Oncology Reports</i> , 2017, 20, 58-61.	0.6	17
81	Risk assessment to guide cervical screening strategies in a large Chinese population. <i>International Journal of Cancer</i> , 2016, 138, 2639-2647.	5.1	16
82	Treatability by Cryotherapy in a Screen-and-Treat Strategy. <i>Journal of Lower Genital Tract Disease</i> , 2009, 13, 174-181.	1.9	15
83	The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. <i>Cancer</i> , 2016, 122, 3682-3686.	4.1	15
84	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. <i>Preventive Medicine</i> , 2018, 111, 429-435.	3.4	15
85	Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 36-42.	2.5	14
86	Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta. <i>BMC Infectious Diseases</i> , 2013, 13, 5.	2.9	13
87	Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. <i>JAMA Oncology</i> , 2017, 3, 1327.	7.1	13
88	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1222-1228.	6.3	12
89	Perceived Susceptibility to Cervical Cancer among African American Women in the Mississippi Delta: Does Adherence to Screening Matter?. <i>Women's Health Issues</i> , 2019, 29, 38-47.	2.0	12
90	Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador. <i>JCO Global Oncology</i> , 2020, 6, 1519-1530.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. <i>Journal of the National Cancer Institute</i> , 2022, 114, 845-853.	6.3	12
92	Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management. <i>International Journal of Cancer</i> , 2022, 151, 1142-1149.	5.1	12
93	Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2348-2355.	3.9	10
94	Comparative Risk of High-Grade Histopathology Diagnosis After a CIN 1 Finding in Endocervical Curettage Versus Cervical Biopsy. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, 137-141.	1.9	9
95	Considerations for HPV primary screening in lower-middle income countries. <i>Preventive Medicine</i> , 2017, 98, 39-41.	3.4	9
96	The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. <i>Preventive Medicine</i> , 2020, 131, 105931.	3.4	9
97	Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus-Positive Screening Test Results. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 127-134.	1.9	9
98	Plasma cytokine levels and human papillomavirus infection at the cervix in rural Nigerian women. <i>Cytokine</i> , 2013, 64, 146-151.	3.2	8
99	Effects of Maintenance on Quality of Performance of Cryotherapy Devices for Treatment of Precancerous Cervical Lesions. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 47-51.	1.9	7
100	Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images. <i>Journal of Clinical Medicine</i> , 2021, 10, 953.	2.4	7
101	An Evaluation by Midwives and Gynecologists of Treatability of Cervical Lesions by Cryotherapy Among Human Papillomavirus-Positive Women. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 728-733.	2.5	6
102	Squamous Intraepithelial Lesions in Cervical Tissue Samples of Limited Adequacy and Insufficient for Grading as Low or High Grade. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 35-45.	1.9	6
103	Comparison of Depth of Necrosis Using Cryotherapy by Gas and Number of Freeze Cycles. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 1-6.	1.9	6
104	Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 27-30.	1.9	6
105	Evaluation of two alternative ablation treatments for cervical pre-cancer against standard gas-based cryotherapy: a randomized non-inferiority study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 851-856.	2.5	6
106	Comparison of immediate colposcopy, repeat conventional cytology and high-risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The ASCUS- <i>COL</i> trial. <i>International Journal of Cancer</i> , 2021, 148, 1394-1407.	5.1	5
107	Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies. <i>Cancer Prevention Research</i> , 2021, 14, 919-926.	1.5	5
108	A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test. <i>Journal of Virological Methods</i> , 2011, 176, 112-114.	2.1	4

#	ARTICLE	IF	CITATIONS
109	Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 383-394.	2.2	4
110	Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city—Lessons learned from the Amazon city of Manaus, Brazil. PLoS ONE, 2021, 16, e0258539.	2.5	3
111	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0865.2021.	2.5	3
112	Spectroscopic Imaging as Triage Test for Cervical Disease. Journal of Lower Genital Tract Disease, 2008, 12, 52-53.	1.9	2
113	Development of a Large Biorepository of Cervical Specimens for the Improving Risk Informed HPV Screening Study (IRIS). Journal of Clinical Virology, 2021, 145, 105014.	3.1	2
114	Accepting the Universal Truths of Cervical Human Papillomavirus Epidemiology in Pursuit of the Remaining Mysteries. Sexually Transmitted Diseases, 2011, 38, 907-908.	1.7	1
115	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	6.3	0
116	Evaluation of Risk-based Colposcopy for Cervical Precancers Detection in the ASCUS LSIL Triage Study [40B]. Obstetrics and Gynecology, 2019, 133, 31S-31S.	2.4	0
117	Abstract CT111: Ablation techniques adapted for low- and middle-income countries. , 2016, , .		0
118	Abstract 2586: Evaluation of risk-based colposcopy in the ALTS trial. , 2016, , .		0
119	Abstract A28: Risk model for clinical management of HPV-infected women. , 2017, , .		0